Source comparison
VIP and Thymosin Alpha-1 for CIRS Research: Side-by-Side Comparison
Before initiating any CIRS peptide research protocol, understanding the mechanistic and practical differences between VIP and Thymosin Alpha-1 is essential for study design and outcome interpretation. Primary Mechanism VPAC receptor agonist. Suppresses NF-kB-m
This comparison does not assign a generated winner or score.
- Before initiating any CIRS peptide research protocol, understanding the mechanistic and practical differences between VIP and Thymosin Alpha-1 is essential for study design and outcome interpretation.
- Primary Mechanism
- VPAC receptor agonist. Suppresses NF-kB-mediated cytokine transcription
- TLR-2/TLR-9 modulator. Promotes IL-2 secretion and CD4+ T-cell differentiation
- VIP addresses inflammatory output; Thymosin addresses immune regulatory capacity
- Target CIRS Pathway
- Cytokine cascade (TGF-beta1, MMP-9, C4a elevation)
- T-regulatory cell dysfunction and CD4+/CD8+ ratio suppression
- Complementary pathways. Explains why combination protocols outperform monotherapy
- Administration Route
- Intranasal spray (bypasses hepatic metabolism)
- Subcutaneous injection (standard peptide delivery)
- Route selection impacts bioavailability and dosing frequency
- Typical Research Dose
- 50mcg per dose, 4× daily
- 1.6mg subcutaneous, 2× weekly
- Intranasal VIP requires multiple daily doses due to 1-2 minute half-life
- Half-Life
- 1-2 minutes (plasma)
- ~2.5 hours (plasma)
- Short VIP half-life necessitates frequent dosing to maintain therapeutic levels
- Storage (Lyophilized)
- -20°C until reconstitution
- Temperature excursions above 8°C denature both peptides irreversibly
- Reconstituted Stability
- 28 days at 2-8°C in bacteriostatic water
- Never freeze reconstituted solutions. Ice crystals break peptide bonds
- Primary Research Outcome
- Cytokine normalization (MMP-9, TGF-beta1, C4a)
- Treg recovery and CD4+/CD8+ ratio restoration
- Outcomes are independent. VIP success doesn't predict Thymosin response